/
ABEO
$6.47+$0.24 (+3.85%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$368.8M
57M shares
52-week range
$4.00 – $7.54
70% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-25.78
Abeona Therapeutics Inc. Common Stock
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
www.abeonatherapeutics.com- Employees
- 226
- IPO / List date
- Sep 19, 1980
- HQ
- CLEVELAND, OH
Held by traders on TradeandTell
No one on the platform currently holds ABEO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 161,082 | $721.6K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2022-07-05 | 1-for-25reverse |
Recent trades on TradeandTell
No one on the platform has traded ABEO yet.
